source
- Cytokinetics heart drug scores in closely watched trialMyqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.BioPharma Dive · 2mo ago↗ source
- Cytokinetics succeeds where Bristol Myers failed in heart muscle diseaseCytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The…Endpoints · 2mo ago↗ source
- Cytospire hauls in $83M for a new type of T cell engagerThe British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.